European Aviation Safety Agency

Acceptable Means of Compliance and Guidance Material to Part-MED

Amendment 1
8 August 2013

1 For the date of entry into force of this amendment, refer to Decision 2013/016/R in the Official Publication of the Agency.
AMC TO PART-MED AMENDMENT 1 – CHANGE INFORMATION

The text of the amendment is arranged to show deleted, new or amended text as shown below:

1. deleted text is marked with strike through;
2. new or amended text is highlighted in grey; and
3. an ellipsis (…) indicates that the remaining text is unchanged in front of or following the reflected amendment.

Amendments

Create a new AMC17 MED.B.095 and a new AMC18 MED.B.095 directly after existing AMC16 MED.B.095 as follows at:

- AMC to Part-MED
  - Subpart B Specific Requirements for class 1, class 2 and LAPL medical certificates
    - AMC for class 1, class 2 and LAPL medical certificates
      - Section 4 Specific requirements for LAPL medical certificates

AMC17 MED.B.095 Dermatology

In cases where a dermatological condition is associated with a systemic disease, full consideration should be given to the underlying illness before a fit assessment may be considered.

AMC18 MED.B.095 Oncology

(a) In the case of malignant disease, applicants may be considered for a fit assessment if:

(1) there is no evidence of residual malignant disease likely to jeopardise flight safety;
(2) time appropriate to the type of tumour has elapsed since the end of primary treatment;
(3) the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low;
(4) there is no evidence of short or long-term sequelae from treatment that may adversely affect flight safety.

(b) Arrangements for an oncological follow-up should be made for an appropriate period of time.

...